RxDoctor Payments DataLook up a doctor →

Harsha Sen, MD

Ophthalmology · Dothan, ALNPI 1255692414

Payments from drug & device makers

$139,548in general payments, 2019–2025

Across 225 payments — averaging $620.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$123K
  • Boehringer Ingelheim International GmbH$7K
  • Boehringer Ingelheim Finland Ky$6K
  • AbbVie$864
  • Genentech USA, Inc.$660
  • Alimera Sciences, Inc.$385
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$7,33466%
  • Food & beverage$3,76934%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$139,548 in reported general payments places this provider in the 95th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$1,679,359
Medicare patients
772
Services billed
19,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate398$12,929
LumiganBimatoprost21$10,415
SimbrinzaBrinzolamide/Brimonidine Tart32$6,530
ProlensaBromfenac Sodium13$4,582
Ketorolac Tromethamine170$3,880
Brimonidine Tartrate122$1,687
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,533
Timolol Maleate55$1,468
Latanoprost154$1,463
Valganciclovir Hcl11$1,315
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim111$977
Atropine Sulfate15$522
Dorzolamide Hcl18$364
ErythromycinErythromycin Base17$160
Cyclopentolate Hcl13$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$864$10,41521 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$46$4,58213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →